HIV-1 antiretroviral resistance: scientific principles and clinical applications
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityAntiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine seriesIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisProfile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelagoThe root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitorIDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platformAn Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 QuasispeciesIdentification of potent maturation inhibitors against HIV-1 clade CUsing drug exposure for predicting drug resistance - A data-driven genotypic interpretation toolHIV-1 drug resistance and resistance testing.HIV-1 Genetic Variability and Clinical ImplicationsGetting to 90-90-90 in paediatric HIV: What is needed?Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Data-intensive analysis of HIV mutations.Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human bloodSmall molecules that inhibit Vif-induced degradation of APOBEC3G.Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysisHIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya."Every drug goes to treat its own disease…" - a qualitative study of perceptions and experiences of taking anti-retrovirals concomitantly with anti-malarials among those affected by HIV and malaria in Tanzania.Influence of quinacrine and chloroquine on the in vitro 3'-azido-3'-deoxythymidine antiretroviral effect.Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithmEffects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenComparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individualsPotent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.High prevalence of PI resistance in patients failing second-line ART in Vietnam.Psychosocial factors in adherence to antiretroviral therapy among HIV-positive people who use drugs.More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Clinical implications of HIV-1 minority variantsResponse to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug Resistance
P2860
Q24628212-6C77EE2C-F95B-4426-8C3C-3A34E412EE15Q27312940-C5ACB742-9FFA-4F82-B54A-19000B38D4B9Q27683977-AD89BF3E-6E71-44DA-AFCB-C2F2D24DE3F8Q28486262-C20A7C8A-988C-42E8-9618-4EDD019C062FQ28538242-0061F910-C5C9-4E48-B1A8-332E5FEC926DQ28539308-021B9494-94ED-4D4E-BD8C-F4FC6013462DQ28543211-1645984B-3A38-4052-8480-C0A6D3AD5DC4Q28554999-725F67F2-5CB8-4684-BDC9-15D52384A950Q28829072-6DBC97F7-A7D5-4173-8310-B575214C20ACQ30000270-F5351178-316B-4C42-916D-B64064F2E592Q30245693-20EE88EB-A595-44B5-835A-1C690650B852Q30352010-40D61517-7AE5-4AE5-B409-C68807E2BEDFQ30385352-F001A6C1-F20C-4E59-8044-3F1DBFA2A21CQ30744184-37ED2976-1A2C-4A71-BEE8-E1610691A646Q30887525-B6CF8380-205B-4F38-9C4B-2B5DDFD35F50Q33634625-4AA71A37-32F3-47EE-8274-D70849B76F09Q33664179-D479F7F9-01A2-4082-B1FC-E62334E6DA9CQ33690506-E5D83996-A8A1-427A-A395-AC222849E1EEQ33857983-1821C371-D538-42B3-A840-9B0E53B1EB59Q34085477-240F4CF6-789F-4B9F-973A-6DBB2739DF1BQ34249966-3CD43731-B87C-4A15-99DD-13E958BB842EQ34549498-D43A16A2-1C35-4BAD-9F94-936B0B074753Q34996394-2F724F2C-B746-4D10-A749-C6B1EF87CD2EQ35191410-C1A8B05F-543C-4FA7-8886-CC65CFC8B5D8Q35497950-AF696242-CA0A-430C-826D-4F5A58586B7FQ35588149-1506608C-F58D-4D4E-BA24-7962FF3667C5Q36050916-8386C800-2478-4B9B-AF5F-A16B1B59F093Q36184910-8693BB51-8EA2-422D-BCCE-580B8619E828Q36205277-84A6A01D-0D8E-496A-92D8-6E1512E3149BQ36246775-40D27F57-E08A-473B-9C7D-97BB616C84FFQ36255602-E0FC32F2-E8DB-45A6-AFAB-C3C0D9FBFF65Q36349683-C33B47A6-B3C3-415D-A0D2-58E5732E377FQ36422328-A7A8D5AB-EEA7-44A6-BE75-53F11BF86782Q36528651-2DBC2D63-2179-44A9-802D-8DCC6FDC08D6Q36551309-B608506D-DC1F-491A-A01D-D70498C812A3Q36599164-5FC1BEE1-6279-4580-923E-94CDEC66D9CBQ36610081-DD5F7ABC-FB8B-455C-91CC-7D9216168A4EQ36721002-50AA9CD8-AB55-4D88-BA8E-4099E17EA729Q36811249-B2DE07BB-B809-4338-A07D-B4388813A3ADQ36900951-E1932081-580D-41DE-BF43-A2B88D765B25
P2860
HIV-1 antiretroviral resistance: scientific principles and clinical applications
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@ast
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@en
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@nl
type
label
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@ast
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@en
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@nl
prefLabel
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@ast
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@en
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@nl
P2860
P921
P1433
P1476
HIV-1 antiretroviral resistance: scientific principles and clinical applications
@en
P2093
Michele W Tang
Robert W Shafer
P2860
P356
10.2165/11633630-000000000-00000
P577
2012-06-01T00:00:00Z
2012-06-18T00:00:00Z
P5875
P6179
1047852303